Liberty One Investment Management LLC Has $722,000 Holdings in Novartis AG $NVS

Liberty One Investment Management LLC lessened its holdings in shares of Novartis AG (NYSE:NVS) by 5.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,965 shares of the company’s stock after selling 339 shares during the quarter. Liberty One Investment Management LLC’s holdings in Novartis were worth $722,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of NVS. WPG Advisers LLC purchased a new position in Novartis during the 1st quarter valued at about $25,000. Tsfg LLC grew its stake in Novartis by 366.0% during the 1st quarter. Tsfg LLC now owns 233 shares of the company’s stock valued at $26,000 after acquiring an additional 183 shares in the last quarter. GFG Capital LLC purchased a new position in Novartis during the 2nd quarter valued at about $26,000. Barrett & Company Inc. purchased a new position in Novartis during the 2nd quarter valued at about $31,000. Finally, MCF Advisors LLC grew its stake in Novartis by 66.0% during the 2nd quarter. MCF Advisors LLC now owns 264 shares of the company’s stock valued at $32,000 after acquiring an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Stock Up 0.3%

NVS opened at $131.78 on Tuesday. The business has a 50 day moving average price of $126.80 and a 200 day moving average price of $118.80. Novartis AG has a twelve month low of $96.06 and a twelve month high of $133.55. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.62 and a current ratio of 0.82. The firm has a market cap of $278.38 billion, a P/E ratio of 19.18, a price-to-earnings-growth ratio of 1.82 and a beta of 0.64.

Analyst Ratings Changes

NVS has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a research note on Thursday, August 21st. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research note on Wednesday, October 8th. The Goldman Sachs Group reissued a “sell” rating and issued a $118.00 price target (down previously from $119.00) on shares of Novartis in a research note on Friday, September 12th. Morgan Stanley raised Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target for the company in a research note on Friday, August 8th. Finally, Wall Street Zen raised Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, Novartis currently has an average rating of “Hold” and a consensus price target of $120.33.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.